Dynamic quotes: Off
|
ETFs with AGN as a Top 10 Holding*Sponsored by:
| Weighting | ETF Name (Symbol) | 100-Day Price Change (%) |
|---|---|---|
| 5.02% | Merrill Lynch Pharmaceutical HOLDRS (PPH) | +5.82 (14.62%) |
| 4.89% | iShares Dow Jones U.S. Pharmaceutical Index Fund (IHE) | +12.92 (14.28%) |
| 4.35% | SPDR S&P Pharmaceuticals ETF (XPH) | +11.99 (19.90%) |
| 3.56% | iShares MSCI Netherlands Index Fund (EWN) | +0.92 (4.33%) |
| 2.06% | Guggenheim S&P 500 Equal Weight Healthcare ETF (RYH) | +11.62 (13.72%) |
|
||
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
We are a multi-specialty health care company focused on developing and commercializing innovative pharmaceuticals, biologics, medical devices and over-the-counter products that enable people to live life to its full potential - to see more clearly, move more freely and express themselves more fully. We discover, develop and commercialize a diverse range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological and other specialty markets in more than 100 countries around the world. We are also a pioneer in specialty pharmaceutical, biologic and medical device research and development. Our research and development efforts are focused on products and technologies related to the many specialty areas in which we currently operate as well as new specialty areas where unmet medical needs are significant. In 2012, our research and development expenditures were approximately 17. ... More ...
Consensus Recommendation |
|
Analyst Info |
|
| Annual EPS Est: | $4.14 |
| Quarterly EPS Est: | 1.2 |
| PEG Ratio: | 1.57 |
|
Mean Recommendation: View Summary / View All |
1.75 |
Data is provided by Zacks Investment Research